There were 189 press releases posted in the last 24 hours and 437,647 in the last 365 days.

Human medicines European public assessment report (EPAR): Skytrofa (previously Lonapegsomatropin Ascendis Pharma), lonapegsomatropin, Growth and Development, Date of authorisation: 11/01/2022, Revision: 4, Status: Authorised

The most common side effects with Lonapegsomatropin Ascendis Pharma (which may affect up to around 1 in 10 people) are headache, joint pain, secondary hypothyroidism (a type of low thyroid function) and reactions at the injection site such as redness, pain, itching or swelling.

For the full list of side effects of Lonapegsomatropin Ascendis Pharma, see the package leaflet.

Growth hormone medicines like Lonapegsomatropin Ascendis Pharma must not be used if the patient has an active tumour or an acute life-threatening illness. The medicine must also not be used for promoting growth in children with closed epiphyses (when the large bones have finished growing). For the full list of restrictions, see the package leaflet.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.